Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MIRA Pharmaceuticals, Inc. - Common Stock
(NQ:
MIRA
)
1.100
+0.050 (+4.76%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
209,819
Open
1.070
Bid (Size)
1.070 (5)
Ask (Size)
1.090 (1)
Prev. Close
1.050
Today's Range
1.050 - 1.100
52wk Range
0.5100 - 5.010
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
December 19, 2024
Via
ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
December 19, 2024
MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in preclinical studies.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
-7.56%
-7.56%
1 Month
-16.03%
-16.03%
3 Month
-0.90%
-0.90%
6 Month
+54.93%
+54.93%
1 Year
+4.76%
+4.76%
More News
Read More
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
December 10, 2024
Via
ACCESSWIRE
EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
December 10, 2024
Via
Benzinga
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
November 20, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
October 28, 2024
Via
Benzinga
Peering Into Mira Pharmaceuticals's Recent Short Interest
September 11, 2024
Via
Benzinga
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
August 26, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 28, 2024
Via
Benzinga
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
October 28, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
October 25, 2024
Via
Benzinga
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
October 21, 2024
Via
ACCESSWIRE
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
October 03, 2024
Via
News Direct
Topics
Cannabis
Exposures
Cannabis
Why Mira Shares Are Trading Higher Today
September 27, 2024
Via
Benzinga
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
September 27, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
September 19, 2024
Via
News Direct
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
September 18, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
September 11, 2024
Via
ACCESSWIRE
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
August 27, 2024
Via
News Direct
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
August 26, 2024
Via
Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
August 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
August 19, 2024
Via
ACCESSWIRE
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
August 12, 2024
Via
ACCESSWIRE
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.